BioSpace News Archive

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023.

NeoGenomics, Inc. (NASDAQ:NEO) (the “Company”), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023.

Navidea Biopharmaceuticals, Inc. announced the introduction of a Fix, Fund, Propel approach to driving the Company’s strategy forward; The Company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended March 31st, 2023.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Biotechnology has published a paper titled “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.”

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 27,250 shares of its common stock to seventeen newly-hired employees, with a grant date of May 5, 2023.

Carisma Therapeutics Inc. announced that Steven Kelly, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 1:00 pm EDT in New York.

Precision BioSciences, Inc. announced that, on April 27, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.

IMV Inc. announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110 and IM-5101-1, has in exercising its discretion determined to delist the Company’s common shares as a result of the Company’s announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,200 shares of the Company’s common stock at an exercise price per share of $19.85, which was the closing price on May 8, 2023, and restricted stock units to acquire a total of 5,600 shares of the Company’s common stock.

Alkermes plc filed its preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming Annual General Meeting of Shareholders.